Analytical Data
-
基因名
aiiM
- Application
-
别名
AHL-lactonase
-
种属
Microbacterium testaceum
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
C6L862
-
表达区间
1-251aa
-
分子量
43.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
aIIIM, a novel recombinant protein, has garnered significant interest in the field of biotechnology and medical research due to its potential applications in therapeutic development and diagnostics. Recombinant proteins, produced through genetic engineering techniques, have revolutionized the way we approach various diseases by enabling the production of high-purity proteins that can mimic natural biological functions. The study of aIIIM specifically focuses on its role in modulating immune responses, which is crucial for developing new treatments for autoimmune disorders, cancer immunotherapy, and infectious diseases. Researchers have been investigating the structural characteristics and functional properties of aIIIM to better understand its mechanisms of action and potential interactions with other biomolecules. The advancement in recombinant DNA technology has facilitated the production of aIIIM in significant quantities, paving the way for high-throughput screening and functional assays to evaluate its efficacy and safety. Moreover, the insights gained from studying aIIIM could lead to innovative therapeutic strategies, making it a promising candidate for future clinical applications. As the demand for targeted and personalized medicine continues to rise, aIIIM's discovery may contribute to the development of novel biologics that improve patient outcomes and quality of life.
